Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.35 +9.8%	$1.44	$0.65 ▼ $17.00	$22.96M	1.19	360,040 shs	2.12 million shs
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$58.48M	1.52	84,300 shs	65,715 shs
INKT MiNK Therapeutics	$14.90 -0.3%	$14.65	$4.56 ▼ $76.00	$67.35M	0.33	157,536 shs	38,436 shs
VRCA Verrica Pharmaceuticals	$5.47 -4.7%	$6.62	$3.82 ▼ $29.70	$51.69M	1.92	45,396 shs	50,701 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	0.00%	+1.50%	-19.16%	+92.03%	-90.92%
DTIL Precision BioSciences	0.00%	+5.31%	-3.69%	+8.30%	-48.81%
INKT MiNK Therapeutics	0.00%	-0.07%	-19.72%	+109.98%	+81.71%
VRCA Verrica Pharmaceuticals	0.00%	-8.22%	-17.25%	-10.58%	-80.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.588 of 5 stars	3.3	4.0	0.0	1.1	0.8	1.3
DTIL Precision BioSciences	4.071 of 5 stars	3.5	1.0	4.6	2.9	1.7	0.6
INKT MiNK Therapeutics	2.784 of 5 stars	3.3	5.0	0.0	1.1	1.7	0.6
VRCA Verrica Pharmaceuticals	4.5946 of 5 stars	3.1	5.0	4.7	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,825.93% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
INKT MiNK Therapeutics	2.60	Moderate Buy	$37.50	151.68% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,362.52% Upside

Current Analyst Ratings Breakdown

Latest CTXR, DTIL, INKT, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$35.00 ➝ $35.00
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
7/18/2025	INKT MiNK Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
DTIL Precision BioSciences	$68.70M	0.85	N/A	N/A	$6.87 per share	0.72
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($4.94) per share	N/A
VRCA Verrica Pharmaceuticals	$7.57M	6.83	N/A	N/A	($1.07) per share	-5.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.08	N/A	N/A	-60.03%	-33.83%	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
INKT MiNK Therapeutics	-$9.51M	-$2.88	N/A	N/A	N/A	N/A	N/A	-227.24%	11/13/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$8.28	N/A	N/A	N/A	N/A	N/A	-115.48%	11/3/2025 (Estimated)

Latest CTXR, DTIL, INKT, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INKT MiNK Therapeutics	-$0.55	-$1.06	-$0.51	-$1.06	N/A	N/A
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.70	$0.02	+$0.72	$0.02	$4.37 million	$12.70 million
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.14
DTIL Precision BioSciences	0.66	5.18	5.18
INKT MiNK Therapeutics	N/A	0.15	0.30
VRCA Verrica Pharmaceuticals	N/A	1.26	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
DTIL Precision BioSciences	37.99%
INKT MiNK Therapeutics	2.87%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
DTIL Precision BioSciences	4.00%
INKT MiNK Therapeutics	22.48%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	17.01 million	15.19 million	Optionable
DTIL Precision BioSciences	200	11.79 million	11.32 million	No Data
INKT MiNK Therapeutics	30	4.52 million	3.51 million	No Data
VRCA Verrica Pharmaceuticals	40	9.45 million	4.35 million	Optionable

CTXR, DTIL, INKT, and VRCA Headlines

Recent News About These Companies

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%

August 22 at 3:25 AM | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.3%

August 22 at 2:11 AM | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

August 14, 2025 | marketbeat.com

Verrica Posts Profit in Fiscal Q2

August 14, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Verrica Pharmaceuticals Regains Nasdaq Compliance

August 12, 2025 | msn.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

August 12, 2025 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Gap Down - What's Next?

July 26, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, DTIL, INKT, and VRCA Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.35 +0.12 (+9.76%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.37 +0.02 (+1.48%)

As of 06:52 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 06:14 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

MiNK Therapeutics NASDAQ:INKT

$14.90 -0.05 (-0.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.65 -0.25 (-1.68%)

As of 05:46 AM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.47 -0.27 (-4.70%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.51 +0.04 (+0.73%)

As of 04:00 AM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time